Gossamer Bio Inc (GOSS) - Total Assets
Based on the latest financial reports, Gossamer Bio Inc (GOSS) holds total assets worth $208.82 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Gossamer Bio Inc - Total Assets Trend (2016–2024)
This chart illustrates how Gossamer Bio Inc's total assets have evolved over time, based on quarterly financial data. Also see market cap of Gossamer Bio Inc for the company's overall valuation and market capitalisation.
Gossamer Bio Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Gossamer Bio Inc's total assets of $208.82 Million consist of 98.3% current assets and 1.7% non-current assets. Review GOSS total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 14.6% |
| Accounts Receivable | $5.34 Million | 1.7% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Gossamer Bio Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See latest Gossamer Bio Inc stock price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Gossamer Bio Inc's current assets represent 98.3% of total assets in 2024, a decrease from 100.0% in 2016.
- Cash Position: Cash and equivalents constituted 14.6% of total assets in 2024, down from 100.0% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 1.7% of total assets.
Gossamer Bio Inc Competitors by Total Assets
Key competitors of Gossamer Bio Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Abivax SA American Depositary Shares
NASDAQ:ABVX
|
USA | $547.14 Million |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Suzhou Zelgen Biopharmaceuticals Co Ltd
SHG:688266
|
China | CN¥3.01 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Galecto Inc
NASDAQ:GLTO
|
USA | $535.44 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
|
Shanghai Shen Lian Biomedical Corp
SHG:688098
|
China | CN¥1.53 Billion |
Gossamer Bio Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.28 | 6.74 | 13.51 |
| Quick Ratio | 3.28 | 6.74 | 13.51 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $141.87 Million | $293.18 Million | $483.67 Million |
Gossamer Bio Inc - Advanced Valuation Insights
This section examines the relationship between Gossamer Bio Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.66 |
| Latest Market Cap to Assets Ratio | 0.34 |
| Asset Growth Rate (YoY) | 1.1% |
| Total Assets | $315.29 Million |
| Market Capitalization | $106.47 Million USD |
Valuation Analysis
Below Book Valuation: The market values Gossamer Bio Inc's assets below their book value (0.34x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Gossamer Bio Inc's assets grew by 1.1% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Gossamer Bio Inc (2016–2024)
The table below shows the annual total assets of Gossamer Bio Inc from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $315.29 Million | +1.08% |
| 2023-12-31 | $311.92 Million | +14.49% |
| 2022-12-31 | $272.45 Million | -20.72% |
| 2021-12-31 | $343.66 Million | -36.29% |
| 2020-12-31 | $539.43 Million | +26.45% |
| 2019-12-31 | $426.60 Million | +78.18% |
| 2018-12-31 | $239.42 Million | +53702.02% |
| 2017-12-31 | $445.00K | +641.67% |
| 2016-12-31 | $60.00K | -- |
About Gossamer Bio Inc
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical tr… Read more